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ABSTRACT  
 
Systems biology is the rapidly growing and heavily funded successor science to 
genomics. Its mission is to integrate extensive bodies of molecular data into a 
detailed mathematical understanding of all life processes, with an ultimate view 
to their prediction and control. Despite its high profile and widespread practice, 
there has so far been almost no bioethical attention paid to systems biology and 
its potential social consequences. We outline some of systems biology’s most 
important socioethical issues by contrasting the concept of systems as dynamic 
processes against the common static interpretation of genomes. New issues 
arise around systems biology’s capacities for in silico testing, changing cultural 
understandings of life, synthetic biology and commercialization. We advocate an 
interdisciplinary and interactive approach that integrates social and philosophical 
analysis and engages closely with the science. Overall, we argue that systems 
biology socioethics could stimulate new ways of thinking about socioethical 
studies of life sciences. 
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The study of socioethical issues in systems biology 
 
 
Systems biology is the heir presumptive of the molecular advances made by 
genomics and associated high-throughput data gathering. Its mission is to 
integrate these extensive bodies of data into a detailed mathematical 
understanding of all life processes with an ultimate view to their prediction and 
control. Numerous governments have prioritized systems biology in their budgets 
for life science research and a rapidly growing body of literature identifies itself as 
systems biology. Despite its high profile and widespread practice, there has so 
far been almost no bioethical attention paid to systems biology and its potential 
social consequences. We will outline some of the most notable issues within a 
broad-ranging comparison of systems biology (including its claimed historical 
background and anticipated applications) with genomics and genetics and the 
socioethical attention they were deemed to warrant. We argue that a key 
characteristic of systems biology is its focus on dynamic processes. This focus 
should counteract a persistent tendency to interpret genomics as the science of 
static DNA molecules. Although we identify some novel social and ethical 
implications of systems biology, an even more important point of our discussion 
is our claim that the study of systems biology could stimulate new ways of 
thinking about socioethical studies of the life sciences and contribute to the 
development of a bioethics that does not merely follow scientific transitions but 
accompanies and interacts with them. We suggest that this interactive approach 
is more properly termed socioethics than bioethics because of its integration of 
social and philosophical analysis. 
 
[See glossary for clarification of biological terms. Currently located after the 
conclusion.] 
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Systems biology 
 
Systems biology is meant to answer the key question raised by genomics and 
associated data gathering: How can the field move from a list of molecular parts 
to a sophisticated and predictive understanding of biological processes? The 
realization that processes and systems do not arise in simple linear ways from 
genomes has forced a broadening of attention to multiple interacting levels of 
biological activity – none of which can be regarded as the most ‘fundamental’ 
(Brent and Bruck 2006). Although it uses the enormous inventories of molecules 
generated by genomics and other ‘omics’ (including proteomics and 
transcriptomics), systems biology must take such data many steps further in 
order to reveal the processes of life and show how systems such as cells, tissues 
and ultimately organisms emerge from collections of interacting molecules.1 Most 
generally, systems biology aims to understand life in its most comprehensive and 
dynamic detail by using mathematical models to integrate high-throughput 
databases and experimental findings (US DOE 2005; Auffray et al. 2003). A large 
body of literature anticipates the ways and means by which systems biology will 
change biology into a more quantified and predictive activity while simultaneously 
overcoming the reductionism often practised in genomics (Ideker et al. 2001; 
Kitano 2002a). While useful at a certain phase of scientific activity, reductionist 
approaches are commonly argued to be insufficient to the task of fully 
understanding life processes (Palsson 2000; Cornish-Bowden et al. 2004).  
 
Scientists and institutions began to gather under the banner of systems biology in 
the late 1990s and it is now one of the biological funding priorities in Europe, the 
US and Japan (US Department of Energy 2005; WTEC Panel 2005; Reiss 2005). 
Two foci of systems biology are human health and environmental remediation by 
                                                   
1 In an earlier discussion of the philosophical issues in systems biology, we described 
two overlapping strands of scientific activity: the majority pragmatic approach, which 
connects molecules into systems from the bottom up, and the minority systems-theoretic 
approach, which works from top-down system principles to understand molecular 
interactions (O’Malley and Dupré 2005).  
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microbes (bioremediation). Biomedical researchers anticipate the development of 
computer models that will integrate biological data from multiple levels for 
predictive diagnosis, treatment and prevention of disease (Hood et al. 2004). 
These models will encompass detailed understandings of molecular 
mechanisms, the effects of perturbing particular processes, and the correlation of 
biomarker patterns with disease states (Ideker et al. 2006; Mustacchi et al. 2006; 
Kitano 2004a; Waters and Fostel 2004). It is anticipated that models of human 
systems designed for drug discovery and development will dramatically improve 
the disappointingly low rate of successful verification of the medical effectiveness 
and safety of chemical compounds aimed at drug targets identified from genome 
sequences. The failures in this area have been attributed to the lack of biological 
insight accompanying sequence discoveries (Butcher 2005; Hood and Perlmutter 
2004; Noble et al. 1999). Bioremediation research informed by systems biology 
expects to integrate multiple levels of molecular and microorganismal interactions 
and design microbial systems able to remedy pollution in areas important to 
humans (Pazos et al. 2003; Lovley 2003). While microbial effects on 
environments have long been known (as have numerous drug targets in 
humans), advocates of systems biology argue that the precise interactions they 
enable and their side-effects cannot be properly understood without systems 
analysis. 
 
For some commentators, systems biology is just old wine in new bottles. They 
see it as either a revitalized form of physiology (e.g.: Bothwell 2006; Strange 
2005) or the youthful descendant of an aspiring enterprise that emerged in 
various forms over the last four decades under the aegis of cybernetics, systems 
engineering or self-organization theory (Westerhoff and Palsson 2004; Huang 
2004). ‘Predecessors’ such as von Bertalanffy’s general systems theory or 
Robert Rosen’s mathematicization of system organization and maintenance are 
often invoked and very occasionally applied (e.g.: Cornish-Bowden and 
Cárdenas 2005; Wolkenhauer 2001). While it remains to be seen how 
distinctively different current systems biology is from earlier approaches and how 
successful it will be in its own right, there is no doubt that the quantity of data it is 
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already integrating, and its emphasis on mathematical modelling of interacting 
molecules and their emergent properties, constitute a shift from earlier genomics 
and genetics approaches, as well as from earlier higher-level functional 
approaches such as physiology (Ideker et al. 2006). And, even if it is important to 
bear in mind the historical context of systems biology, earlier forms of systems-
theoretic biology were neither very practical nor biologically informed (Kitano 
2002b). Contemporary systems biology appears already to be both of these.2  At 
the very least, the sheer volume of molecular data available to contemporary 
systems biologists may suffice to transform a difference of degree to a difference 
of kind. 
 
Social commentators may be disturbed by what they perceive as the 
exaggerated claims of systems biology and what it can and will deliver, especially 
in respect to human health. A similar rhetoric accompanied the development of 
genomics and many of those promises have still to be realized (McGee 2003). 
That disappointment, however, lies with genomics practised primarily as a 
sequencing endeavour. Systems biology will arguably realize genomics as a fully 
fledged science, in which true biological insight is gained by using a variety of 
tools to integrate DNA data with many further levels of biological information. 
Nobody is promising immediate biological enlightenment and instant cures with 
systems biology. Many advocates temper their convictions that systems biology 
is already making contributions to biological knowledge and therapeutic 
interventions with explicit acknowledgements of how far the field has to go before 
it achieves a genuine capacity for prediction and control (e.g.: Cassman et al. 
2005; Butcher et al. 2004; Mustacchi et al. 2006; Cornish-Bowden 2005).  
 
                                                   
2 We base our simple assessment of practicability on the proliferation of literature about 
the importance of systems biology’s findings (Bork 2005) and the amount of funding and 
science policy recognition the field has achieved internationally (WTEC 2005). More 
subtle assessments of what constitutes success in respect to contemporary systems 
biology will have to wait for a longer-term analysis of the achievements of newly created 
institutions of systems biology, the published findings they produce and their impact on 
associated subfields of biology. 
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For many scientists, it is systems biology’s inextricable commitment to 
multidisciplinary investigation that provides the greatest challenge to its future 
success (e.g.: Hood and Perlmutter 2004; Liu 2005; Kling 2006). A truly 
integrated combination of insights and tools from a number of biological, 
mathematical and computational disciplines is central to every anticipated 
achievement of systems biology. Although interdisciplinarity is frequently raised 
as an issue of social organization, almost none of the broader discussions of 
systems biology yet addresses the socioethical issues that may arise with the 
development of the field, despite the fact that such issues were key concerns of 
the human genome sequencing projects. 
 
 
From the ELSI of genomics to the socioethics of systems 
biology 
 
The Human Genome Project (HGP) had an embedded programme for ethical, 
legal and social implications (ELSI) that allowed the exploration of a plethora of 
bioethical questions ranging from privacy concerns to the commercialization of 
life (Patrinos and Drell 1997; see also Table 1, Column 1). Although social 
scientists and philosophers often criticized HGP ELSI for its lack of autonomy 
from the science (Clayton 2001) and scientists attacked some of its projects for 
their triviality and irrelevance (Marshall 1996), the ELSI investigation of genomics 
nevertheless flourished and expanded within the sphere of human genomics. 
There was very little ELSI attention to spare for the genomics of other organisms 
(we will attempt to show below the benefits of expanding this focus in systems-
based socioethics), and the issues raised were not, overall, conceived to be that 
different from the social and ethical issues raised by genetics (e.g.: Robertson 
2003). Just as genomes were supposedly straightforward amplifications of 
genes, so the ELSI study of genomics was mostly considered an amplification of 
the study of ethical, legal and social studies of genetics. 
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Genome sequencing, however, is only the barest beginning of research that 
might eventually realize socioethical concerns, whereas systems biology is 
currently considered to be the most promising scientific vehicle for bringing such 
implications into being. Why, then, is systems biology so far exempt from social 
and ethical considerations? We believe the main reason that there are at best 
minimal gestures towards socioethical programmes in systems biology 
manifestoes (e.g.: US DOE 2005: 79, 196) is because the scientific object in 
question is a far more elusive set of processes than the object initially sought in 
genomics. Although ELSI discussions of genomics were often critical of 
metaphors equating genes or genomes with blueprints or programmes for life 
(Nelkin 2001), many of these analyses nevertheless addressed genomes as if 
they were static definable entities that ultimately determined the properties of 
organisms and human nature (Ashcroft 2003; Lewens 2002; Richards 2001). 
Although some scientists contributed to this view (see Suter 2001), the science 
itself was rapidly unable to sustain such genomic determinism. Sequences were 
obviously not the answer to questions about life but merely contributors to the 
parts list that could be used within a more integrative process-focused approach 
(Bains 2001; Brent 2004).  
 
Systems biology’s core concept of a system is far fuzzier than that of a genome 
sequence (O’Malley and Dupré 2005; Fox Keller 2005).3 Systems are generally 
conceived of as dynamic processes but currently anything from a few interacting 
molecules to entire ecosystems may be covered by the label (Hood and 
Perlmutter 2004). While systems can be mapped on to a hierarchy of biological 
objects, such as cells or organisms, the concept is not so restricted as to exclude 
a range of subcellular ‘systems’ (e.g.: biochemical pathways, genomes) or 
metaorganismal ‘systems’ (e.g.: cooperative bacterial communities). The range 
                                                   
3 There has been little ontological discussion about genomes amongst scientists or 
bioethicists. Scientists have tended to restrict their abstract discussions of genomes to 
the metaphors used to describe them (e.g.: Avise 2001), whereas philosophers of 
biology have reserved their fascination for gene concepts (e.g.: Stotz et al. 2004 – 
although see Dupré 2004 for some speculations about ontological problems concerning 
the genome).  
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of properties that systems must have (e.g.: robustness) and how these will be 
detected is a growing sub-theme of systems biology (e.g.: Alon 2003; Csete and 
Doyle 2002; Kitano 2004b). Through an understanding of these properties, some 
systems biologists believe they will come to know their objects (systems) more 
fully than can be achieved by narrow focus on the components of the systems.  
 
The complex nature of systems complicates attempts to envision the ethical, 
legal and social issues that will be raised by systems biology, and may lead to 
the view that the investigation of any such issues can be deferred. Although it is 
unlikely that anyone will argue that systems biology is free of social implications, 
we believe it is also unlikely that issues raised with respect to the HGP and 
associated genomic projects could be carried over to systems biology without 
significant rethinking. If we take systems to be entities that encompass sets of 
dynamic interactions and then compare this notion to the static qualities often 
attributed to genes and genomes, we can gain an initial sense of the ways in 
which novel or reconceived socioethical issues might arise in relation to systems 
biology. 
 TABLE 1:  Static versus dynamic socioethical approaches 
Socioethical issue  Static genocentric 
interpretation 
Dynamic systems reinterpretation Consequences of 
reinterpretation 
Identification, privacy and 
discrimination  
E.g.: Insurance or employment 
discrimination because of genetic 
test results; civil liberty 
infringements (Greely 1998; 
Anderlik and Rothstein 2001) 
DNA dictates health status 
and because it is biologically 
‘exceptional’ its investigation 
must be covered by special 
regulation (Suter 2001) 
Health and illness are both dynamic 
states which result from complex 
interactions of multiple genes, other 
molecules and environmental factors 
Genetic tests say very little 
about biological mechanisms 
and processes, and in the 
context of multilevel biological 
insight, genetic 
‘exceptionalism’ is a fallacy 
Identity and ancestry 
E.g.: Conflation of social and 
biological classification (Brodwin 
2002; Foster and Sharp 2002)  
Genomes as souls (Mauron 2001)  
DNA is a fixed marker of 
ancestry and identity and the 
most fundamental repository 
of humanness 
DNA is one of the many constituents 
of our biological make-up, and 
multilevel interactions and emergent 
properties are much more likely to 
give us insights about human 
characteristics 
Relying on DNA to reveal 
identity, ancestry and human 
nature will lead to an 
impoverished understanding 
of ourselves and others 
Genome modification and the 
integrity of life 
E.g.: Environmental contamination; 
violation of nature (Nuffield Council 
on Bioethics 1999; Reiss and 
Straughan 1996)  
Because genomes are the 
fundamental basis of life, 
changing any part of the 
genome will change the 
organism in a fundamentally 
‘unnatural’ and negative way 
 
The organism is a product of many 
interactions, including natural genetic 
engineering 
Genetic engineering is a 
complex process that must 
be understood in a broader 
biological context 
Ownership and commercialization 
of genes, genomes and genetic 
information 
E.g.: Who owns individual genetic 
information? Is life ownable? Does 
DNA patenting block further 
research? (Robertson 2003; Rifkin 
1998; Heller and Eisenberg 1998) 
A gene is a discrete and 
ownable stretch of DNA with 
clear causal properties 
A gene’s effect is contingent on 
genomic, cellular and other 
environmental contexts. If DNA as 
information is patentable, then a 
hierarchy of biological information has 
also to be considered patentable 
The current gene patenting 
paradigm cannot deal 
adequately with systems 
understandings of DNA and 
other biological material 
 New socioethical themes in systems biology 
 
Although Table One gives a general sense of how not to think socioethically in 
relation to systems biology, a more constructive discussion is also needed about 
new socioethical issues that arise in and around the field. Very little work has 
been done on any of these, but there is a small body of literature (or 
extrapolations that can be made from it) that allows us roughly to parallel the ‘old’ 
genomics categories in the table with ‘new’ systems biology ones. Each category, 
however, takes on different dimensions in relation to systems approaches and 
some of the following discussion – because of the immaturity of systems biology 
– is necessarily anticipatory and prospective. Nevertheless, if the bioethics 
community shifts its attention away from genomics and genetics to systems 
biology, it will have to address at least the issues we raise below. 
 
In silico testing 
The ethics of testing in the form of privacy and discrimination concerns were a 
major bioethical theme in genetics and genomics,4 but it is very probable that 
systems biology will give rise to some rather different questions about testing. 
One of the most attractive aspects of systems-biologic approaches for industry is 
the science’s much touted capacity to move experimentation on living organisms 
or in vitro biological material to computer simulations of biological systems (Mack 
2004; Mucke 2005). It is anticipated that in silico drug testing – not the province 
solely of systems biology, but an important component of it – will allow extensive 
understanding of side-effects and benefits of chemical interventions before 
standard clinical trials. It could thus achieve a huge reduction in the current costs 
of drug development, even as markets fragment towards pharmaceutical 
products for sub-populations and possibly individuals (PricewaterhouseCoopers 
1999; Musante et al. 2002; Butcher et al. 2004). Many of the companies that 
                                                   
4 McGuire and Gibbs (2006) discuss how systems biology may straightforwardly 
increase privacy risks. 
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presently advertise systems-biological approaches are exploiting a range of in 
silico capacities to simulate disease courses and therapeutic responses to 
simulated interventions at discovery, pre-clinical and clinical stages (e.g.: Stokes 
and Arkin 2005; Mack 2004; Uehling 2003).  
 
A key socioethical issue that needs to be considered in relation to this aspect of 
systems biology is whether in silico testing will ever have the same legal status 
as in vitro or in vivo tests, or whether in silico results will always require non-
simulated experimental confirmation. The political and economic advantages of 
side-stepping animal testing have often been seen as one of the significant social 
advantages offered by systems biology (e.g.: UK Engineering and Physical 
Sciences Research Council 2004; Noble et al. 1999). This commonly perceived 
benefit may, however, become complicated by doubts about the trustworthiness 
of transferring in silico results to in vivo treatment. We anticipate, however, that 
the possibility of minimizing clinical trials based on animals will be one of the 
most warmly welcomed social benefits of systems biology.  
 
Cultural understandings of life  
A broad area of enormous interest for future socioethical commentary will be the 
translation of systems biology into what we call cultural understandings of life. 
This category encompasses and possibly transforms the identity and ancestry 
themes that arose in earlier genomics. The shift from perceiving the essence of 
life to be encapsulated by a static material thing to seeing life as a fluid and 
complex process in dynamic environments is a major one. Although this change 
is a premise of systems biology rather than its outcome, the increasing visibility of 
systems biology could have a major role in increasing public understanding of 
this insight. Of course, given the continuing vagueness of the concept of a 
system, it may be argued that systems biology is unlikely to capture the public 
imagination at all (e.g.: Wynne 2005). Instead, its subtle claims of complexity and 
emergence may be overwhelmed by traditional assumptions of reductionism and 
determinism because of systems biologists’ insistence on the prospects for 
greater prediction and control. Misleading but powerful simplifications of the 
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nature and function of DNA have persisted throughout the genomics era 
(Ashcroft 2003) and cultural translations of systems could also attribute supreme 
determinative status to DNA or other molecules.5 The sophistication of systems 
biology’s shift away from the focus on DNA sequence to more complex biological 
processes may not be exactly reproduced in public discourse but it need not take 
the ‘simplistic determinism’ avenue of interpretation. The notions of ‘whole’ and 
‘complete’ that accompany scientific talk about systems (e.g.: Selinger et al. 
2003) could easily prove at least as culturally attractive as genetic reductionism, 
and even a loose consideration of systems could change some linear and 
unicausal ways of thinking about the natural world.6 
 
One example of the antidote offered by this extended view can be found in 
metagenomics, which is the study of the DNA of entire microbial communities in 
natural environments (Handelsman 2004). Although currently mostly about 
sequencing and gene discovery, the ultimate aim of metagenomics is to study the 
DNA of communities of organisms (rather than individual genomes) and 
community interactions from an integrated systems perspective (Rodríguez-
Valera 2004; DeLong 2002). These system-based understandings will further 
illuminate the extensive commensalisms between, for example, humans and 
microbial communities (Nicholson et al. 2004; Bäckhed et al. 2005; Relman and 
Falkow 2001), and demand an appreciation of the deep interdependences within 
                                                   
5
 One epistemological point we would emphasize here is that although systems biology 
does aspire to prediction and control, its predictiveness is not simplistically deterministic. 
Systems biologists do want to understand causal relationships but these are repeatedly 
acknowledged (through the bitter experience of research failure rather than philosophical 
conviction) to be about complex loops of interaction that resist linear causal modelling. 
Systems biology models will be able to specify the ‘possibility space’ for system 
behaviour rather than make exact predictions of a single behaviour (see Palsson 2000 
for a good discussion). There are, of course, different strands of systems biology and 
some are narrower than others, but we doubt any future historical overview of systems 
biology will find that its practitioners adhered to simplistic reductionist and determinist 
analysis. 
6 While popular forms of holist thinking do exist (Lovelock’s Gaia hypothesis amongst 
them), systems biology in scientific discourse restricts itself to definable systems which 
are tractable to modelling and simulation. Overall, these systems are rather resistant to 
the language of goals and intention that usually accompanies the more mystic views of 
large systems (Volk 2006). 
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the biodiversity that constitutes the human body.7 Although microorganisms have 
not commonly fallen into the category of life-worth-caring-about for many 
members of the public and even non-microbiological scientists (Nee 2004), the 
widely publicized achievements of early metagenomics (e.g.: Venter et al. 2005; 
Tyson et al. 20058) and their potential to reconfigure ideas about how life is 
organized may change public indifference. Broader discussion of microbial 
systems might also lead to a different conservation ethic, in which interacting 
components and levels are more carefully appreciated than is captured in 
conventional talk of ‘the environment’. More generally, we believe that a systems 
biology socioethics will find it hard to justify a purely human focus, even if human 
health research retains its paramount focus for bioethicists. 
 
Biological modification 
Cultural understandings of life lead directly into the next issue, which shifts the 
concern from what life is to what can be done with it. The consequences of 
biological modification was an ELSI topic of enormous importance for the 
reception of genomic technologies and products, most damagingly exemplified in 
the GM controversy, which – in Europe at least – led to the failure of several lines 
of crop research and commercial products (Rifkin 1998; Frewer et al. 2004). One 
possible achievement of systems biology will be to give scientists the capacity to 
synthesize and intervene in life processes in radically new ways in the forms of 
synthetic biology (Church 2005; Benner and Sismour 2005) and nanosystems 
biology (Heath et al. 2003; Zandonella 2003). Although systems biology is not 
identical to or necessarily inclusive of synthetic biology, the two connect in their 
conceptualization of systems as ‘designed’9 and engineerable (Brent 2004). 
Synthetic systems research may eventually combine with the development of 
                                                   
7 For further discussion see O’Malley and Dupré (in press).    
8
 Popularly cited examples of metagenomics include Venter et al’s vast inventory of 
genes in the Sargasso Sea and Tyson and colleagues’ analysis of the metagenome of 
the microbial community living in highly acidic mining sites. 
9
 This attribution of design is not a metaphysical one (as intelligent design ‘theory’ is) but 
an epistemological approach to system understanding that attracts a different range of 
criticisms (see O’Malley and Dupré 2005). 
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artificial molecular machines that mimic all aspects of life processes (Drexler 
2005) and thereby raise profound questions about the creation of artificial life. 
 
While the interface between synthetic biology and systems biology is frequently 
talked about in regard to human health (e.g.: Kitano 2002a), it has also excited a 
great deal of environmental and microbiological attention. Eco-engineering, or 
bioremediation achieved by stimulating indigenous microbes (rather than 
modified lab cultures) to degrade pollutants, is anticipated as a solution to the 
older and frequently unsuccessful approach of genetically engineering microbes. 
The latter involved ‘DNA cut and paste exercises’ couched within greatly 
simplified understandings of biological processes (Cases and de Lorenzo 2005; 
Sayler and Ripp 2000). Eco-engineering depends on better knowledge of system 
processes and how the activities of natural communities of interacting organisms 
can be enhanced to decontaminate a wide variety of ecosystems (Pazos et al. 
2003; Newman and Banfield 2002). The scientific shift from genetic engineering 
to eco-engineering (or systems engineering) is an important one, and it may 
enable a different discourse about the social consequences and concerns of 
such interventions. A broader view of genetic engineering – a view that would 
include the extensive horizontal gene exchange that occurs naturally in microbial 
communities – is a potential social side-effect of a more public discussion of eco-
engineering research. Molecular insights into ecosystem interactions would not 
necessarily change ideas about the acceptability of genetic modification but they 
may change some of the ways those arguments are attacked and defended. 
 
Current discussions amongst scientists about social and ethical issues in 
synthetic biology take a traditional focus on developing safeguards to prevent the 
loss of control of engineered cells and organisms (Pennisi 2005; Check 2005; 
Ferber 2004). The potential social concerns go much deeper and wider than risk 
analysis, however, and are connected to the implications we noted above for a 
general cultural understanding of life based on systems. These understandings 
are likely to resonate with a range of ideas about modification and its 
acceptability. Although much of the engineering and synthesizing of cells, 
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organisms and environments will happen at the microbial level (US DOE 2005) – 
and microbes, as we have noted, often evoke little interest beyond concerns 
about possible pathogenicity – public sensitivity to human, other animal and plant 
applications is likely to be high. There is a widespread Western cultural distaste 
for engineering metaphors when applied to living entities and life processes 
(Fujimura 2005), and systems biology often insists upon and indeed celebrates 
an engineering perspective (e.g.: Ideker et al. 2006; Brent 2004; Csete and Doyle 
2002). The whole notion of synthetic biology brings up deep metaphysical 
questions about life and what is entailed by the artificial creation of living entities 
from ‘non-natural’ constituents or the introduction of unnatural activities in 
naturally existing organisms or communities. While these are challenging issues 
for which we have no ready answers, we believe that a discussion informed by 
systems understandings is likely to be more realistic than one premised on a 
static notion of a genome. However the debates over synthesized microbial cells 
are managed, they will have immensely important consequences for the distant 
future when synthesized human cells are created.  
 
Commercialization 
Commercialization, the last of the socioethical themes in genomics distinguished 
above, provides a good illustration of the complexities a systems-biologic 
perspective introduces to social and ethical discussions of science. When DNA 
sequences were first patented they were treated just like any other chemical 
compound, as ‘compositions of matter’ with obvious causal properties. We have 
seen a movement away from this chemical analogy in a few patent applications 
which have attempted to claim genomic sequence in computer-embodied or 
‘informational’ form (O’Malley et al. 2005; Maschio and Kowalski 2001). Systems 
biology is perceived by a number of scientists and commentators to be primarily 
an informational science (e.g.: Hood and Galas 2003; Allarakhia and Wensley 
2005), in that it is built on knowledge of multiple biological levels and its 
discoveries and applications are going to be achieved computationally. These 
commentators argue that systems biology will radically push the patenting and 
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commercialization process further away from biological material and towards 
information (Allarakhia and Wensley 2005; Hood, in Compton 2001). 
 
There have already been a few successful patent applications in systems biology 
and a great many more are pending (Russell 2006a; Nature Biotechnology 
2005). However, it is not clear that these patents and patent applications are 
attempts to gain ownership of biological information in the same way that patents 
of DNA sequences are. Most existing systems biology patents and applications 
are for computer tools that use biological information in order to make predictions 
and effective interventions.10 The patents are therefore mathematical 
representations of biological processes (conceived of as systems). They 
manipulate information and make it clinically or scientifically meaningful (Russell 
2006a; Goldman 2002). Some of these biosimulation tools carry names such as 
‘Virtual Patient’, ‘Virtual Human’ or ‘Visual Cell’ (Uehling 2003). They are not yet 
very sophisticated but are already achieving useful results, showing, for example, 
the likelihood of adverse side-effects before expensive drug development is 
initiated. 
 
If we think about systems biology patents in the context of public concern about 
DNA and other biotechnology patents, there are several potential broader social 
responses, both negative and positive. On the negative side, because models in 
systems biology may be perceived as approximations of ‘life itself’, their 
commercialization could be interpreted as a greater threat to conceptions of the 
integrity or sanctity of life than was the patenting of DNA sequence. Also on the 
negative side, computer-generated models have many similarities with computer 
software, the patenting of which is highly contentious because of fears of 
monopolization by large corporations (Perchaud 2003). 
 
                                                   
10
 Other ‘systems’ patent applications, however, appear to revert to traditional 
composition of matter patents and claim interacting molecules rather than anything 
obviously informational (see Allarakhia and Wensley 2005, Table 2). 
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There are more positive possible social responses to the commercialization of 
systems biology, however. Since systems biology will involve the patenting of 
representations of biological entities rather than the entities themselves, systems-
biologic patents may allay the concerns raised above about the private ownership 
of life. Systems biology could thus transform biological patenting into a less 
contentious activity – at least until the advent of the next wave of systems biology 
patents and commercial products, which will possibly be based on synthesized 
life processes. With the rise of synthetic biology alongside systems biology, 
patenting may bifurcate into the computer-based tools produced by systems 
biology and the material objects produced by synthetic biology. The 
commercialization of the latter will sharpen general public discussion about 
synthetic life and its relationship to natural living systems. 
 
A further issue that bears on the social concerns about what is and should be 
ownable is the anticipation that systems biology patents may severely constrain 
the data-sharing that is necessary for the science to develop. When 
interconnected levels of system models are covered by different patents, the 
result may be ‘patent thickets’ that inhibit research and deter innovation. The 
situation Heller and Eisenberg (1998) famously called the ‘tragedy of the anti-
commons’ in relation to genomic research could thus be greatly exacerbated in 
systems-biologic research because the study of biological systems requires even 
greater cooperation and collaboration of many different specialist groups than did 
genomics (Rai 2005). 
 
For these reasons, the ownership and commercialization issues raised by 
systems biology could be interpreted to demonstrate that an overhaul of the 
intellectual property regime in relation to biological inventions is long overdue 
(Hood in Compton 2001). Collaborative ownership regimes11 may be a more 
                                                   
11 Open source is one such collaborative ownership regime that could be considered. In 
bioinformatics, much existing software is open source and this is also the case for 
emerging systems biology software (such as Systems Biology Mark-up Language). 
Research findings made at the lab bench may be more difficult to fit into this mould, 
however (see Rai 2005). 
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practical alternative in the age of large, highly collaborative biological research 
programmes. For example, some systems biologists and commercial developers 
are talking of setting up an international database for computational models in 
which models would have to be made freely accessible or scientific papers based 
on them would not be accepted for publication (Russell 2005; Stokes and Arkin 
2005).  
 
An opposing view, however, is that radical changes to the existing intellectual 
property regime are not necessary, and that modifications of the current system 
would be sufficient to ensure that patents in systems biology avoid some of the 
problems created by genomic patenting. For example, some companies have 
been granting non-exclusive licenses for their biosimulation tools (e.g.: Gene 
Network Science’s ‘VisualCell’). If broad licensing becomes general practice in 
the commercialization of systems biology, research obstruction may not occur. 
Another suggestion is that the best way to deal with developments in systems 
biology is to make sure that inventors do not take out overly encompassing 
patents, which – if granted – could be extended in the future to cover presently 
unknown functions of the invention (Allarakhia and Wensley 2005). Overall, 
however, the novelty of systems biology means that few of the commercialization 
issues are yet obvious and straightforward. At this early stage, the main point we 
would make is that socioethical engagement with systems biology’s commercial 
potential could influence its development, and thereby achieve more than would 
post-hoc descriptive work. 
 
 
 
Concluding reflections on the socioethical study of systems 
biology 
 
All these developing issues, while foreshadowed by earlier ELSI and bioethical 
treatments of genomics, take the discussion into new realms that are potentially 
topics of great mutual interest for scientists, the general public and social 
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commentators. The socioethics of systems biology may, however, require even 
more than an agenda expansion and reorientation of ideas. We believe systems 
biology challenges some assumptions about how the implications of scientific 
developments should be studied. We argued earlier that the dynamic nature of 
systems meant that approaches concerned with static genes and genomes would 
not be adequate, but here our argument for a different approach focuses on the 
organization of the science – most specifically in regard to the interdisciplinary 
and interactive nature of the inquiry appropriate to systems biology. 
 
Systems biology is interdisciplinary not for its own sake but in response to 
perceived scientific imperatives; similarly, systems biology bioethics may have to 
make genuine and transformative interdisciplinary analyses in order to 
understand its complexly interacting objects. Interdisciplinarity does not mean 
that all disciplines contribute equally or indistinguishably to the inquiry, but that 
different lines of investigation provide enhanced understandings of the complex 
phenomena with which the field is concerned. Jason Robert (2005) thoughtfully 
anticipates this necessity in what he calls ‘systems bioethics’, which – although 
generally about a systems approach to the bioethical study of any life science – 
embraces a wide-ranging socially contextualized study of bioethical issues that is 
highly appropriate for systems biology itself.  
 
Although there has been considerable discussion about the integration of social 
scientific inquiry and bioethical reflection (e.g.: Light and McGee 1998; Zussman 
2000; Hedgecoe 2004; Borry et al. 2005), a considerable distance has been 
maintained between the two in spite of and perhaps even because of that 
debate. In our view, this separation is not a sustainable one and that is why we 
use ‘socioethics’, rather than bioethics, to describe the potential study of systems 
biology. All of the issues we raise above show how ethical analysis cannot be 
conducted in isolation from sociocultural context. In other words, ethical analysis 
is always localized, with its very questions the product of specific social and 
cultural circumstances. Each issue has important social dimensions, both in the 
ways it is constructed and the ways it may be addressed. This is obvious even in 
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this highly prospective analysis of systems biology issues, and we do not expect 
them to become simpler as the capacity of the science increases and public 
attention to it grows. 
 
Not only do we advocate much closer interdisciplinarity, but also a process of 
inquiry that is more interactive – not just between social scientists and 
bioethicists but between socioethicists and scientists.12 In the old bioethics or 
ELSI paradigm, the role of social scientists and ethicists was to ask, ‘Here is the 
science: what are its implications?’  We acknowledge that some contributors 
resisted notions of a clear line of demarcation between natural and social worlds 
and a linear flow from one domain to the other (Brown et al. 2000), but that was 
not the standard approach to inquiry. We believe a more valuable socioethical 
approach to systems biology would study systems biology as it develops, rather 
than waiting until the science has already set its course. Because systems 
biology socioethicists would have to study ongoing and emerging research, they 
would need to have close connections with the scientists themselves – 
something we have found systems biologists are open to because of their 
genuine sensitivity to many of the issues we have described.13 The tightrope of 
being either too close to or too far from the science (Nature Editors 2006; Pilcher 
2006) is one that we believe can be navigated, but it requires a new way of 
thinking about the involvement of bioethicists – one that goes beyond the ‘ethical 
advice’ model. As well as providing better engagement with the research itself, 
an interactionist approach also helps anticipate (and to some extent shape) the 
emerging social issues. This engagement also has the potential for the mutual 
transformation of the ideas of both the scientists and those who study them.  
 
Take, for example, the issue we highlighted above of creating life. We noted that 
at present, scientists are grappling with ‘social’ issues of synthetic biology, and 
                                                   
12
 Even very sophisticated socially contextualized arguments often slip into a simple 
biology-versus-society (or culture) framework (e.g.: Levy and Lotz 2005).  
13 We are currently engaged in a sociological study of the institutionalization of systems 
biology in the UK, US and Japan.  
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that these are largely perceived as those of anticipating and preventing the 
potential harms of creating novel life forms. One obvious problem is to decide 
what constitutes such a creation as a living entity. It is not enough for scientists to 
come up with a technical definition of life that fits their scientific context. They 
also have to take into account the deep public unease – in most cultures, 
however differently grounded – with the very idea of creating life. Risk analysis 
and control are secondary to and probably dependent on finding and working 
effectively with a concept of life that meets the expectations of different social 
groups, although such concepts cannot be imposed by any one of these groups. 
And, as much as careful socioethical analyses of ‘life’ may shape scientific 
agendas, so scientific work may change broader cultural expectations of how to 
understand life and interventions in it. Conceptual negotiation will be the only way 
in which the profound and contentious issues of synthetic systems will be 
productively discussed. We anticipate, therefore, that such interactions will have 
to be iterative, with the provision of appropriate forums for negotiation between 
scientists, socioethicists and other social groups.  
 
In this context of understanding interaction, it is important for the bioethics 
community to consider the broader cultural impact of its representations of the 
science. It is worth reflecting how ethics-based critiques of DNA research appear 
to have reinforced genocentric thinking and squeezed socioethical discussion 
into a very narrow framework. In addition, the bioethical and social scientific 
focus on human genomics may have taken public attention away from numerous 
other aspects of genomics, such as comparative and microbial genomics. A 
better grasp of systems biology – at all levels of biological organization – could 
prove an antidote to this tendency and the arbitrary limits it imposes on an 
engagement with the science. 
 
Overall, we believe that socioethical engagement with systems biology offers an 
opportunity for a new approach to asking and answering social questions in 
science, in which much closer collaboration between those concerned with the 
life sciences could underpin scientific, social, legal, ethical, political, cultural and 
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economic discussion. Interdisciplinary interactive collaboration could 
fundamentally change the relationships between life scientists and those who 
study them, as well as the way we think about bioethics.  
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GLOSSARY  
Biomarker 
A biological characteristic (often molecular) used as an 
indicator of a larger biological process (normal, disease 
related, or a response to therapy) 
Bioremediation 
The use of microorganisms to remove contaminants from 
environments through the chemical reactions involved in 
microorganismal metabolism 
Biosimulation 
The use of computer models to conduct virtual tests of 
hypotheses on simulated biological entities and processes 
Drug target 
Molecules (mostly proteins) that are identified as disease 
relevant and made the therapeutic target of introduced 
chemical compounds (drugs) in order to change the disease 
process 
Genocentric 
A perspective that places DNA (genes or genomes) at the 
centre of attention, and as causally primary in biological 
systems. Usually used pejoratively 
Genome All the genetic material of an organism  
High-throughput 
 
The use of automated equipment and software to describe 
rapidly and comprehensively all the elements of a biological 
entity (such as genomes) or to conduct large-scale 
experiments (e.g.: screening hundreds of drug compounds 
against drug targets) 
In silico Created or modelled on a computer system 
In vitro 
The study of biological material in a test tube or other 
experimental setting rather than in an organism (in vivo) 
Metagenomics 
The study of the DNA of microbial communities in their natural 
environments (in situ) 
‘Omics 
A suffix or stand-alone word that indicates a study of the 
complete set of components involved in different levels of 
cellular and organismal activities 
Proteomics 
The study of all the protein products of a genome in an 
organism (or cell) in a particular set of conditions 
System 
A higher level entity that emerges from the interactions of 
components of a biological entity. 
Transcriptomics 
The description and analysis of all the expressed (or 
‘transcribed’) elements of a genome in specific conditions 
 
 
 24 
 
REFERENCES 
 
Allarakhia, M., and Wensley, A. 2005. Innovation and intellectual property rights 
in systems biology. Nature Biotechnology 23: 1485-1488. 
 
Alon, U. 2003. Biological networks: the tinkerer as an engineer. Science 301: 
1866-1867. 
 
Anderlik, M. R., and Rothstein, M. A. 2001. Privacy and confidentiality of genetic 
information: what rules for new science? Annual Review of Genomics and 
Human Genetics 2: 401-433. 
 
Ashcroft, R. E. 2003. The double helix 50 years on: models, metaphors, and 
reductionism. Journal of Medical Ethics 29: 63-64. 
 
Auffray, C., S. Imbeaud, M. Roux-Rouquié, and L. Hood, 2003. From functional 
genomics to systems biology: concepts and practices.  Compte Rendus Biologies 
326 (10): 879-892.  
 
Avise, J. C. 2001. Evolving genomic metaphors: a new look at the language of 
DNA. Science 294 (5540): 86 – 87. 
 
Bäckhed, F., R. E. Ley, J. L. Sonnenburg, D. A. Peterson, and J. I. Gordon. 2005. 
Host-bacterial mutualism in the human intestine. Science 307: 1915-1920. 
 
Bains, W. 2001. The parts list of life. Nature Biotechnology 19: 401-402. 
 
Benner, S. A., and Sismour, A. M. 2005. Synthetic biology. Nature Reviews 
Genetics 6 (7): 533-543. 
 
 25 
Bork, P. 2005. Is there biological research beyond Systems Biology? A 
comparative analysis of terms. Molecular Systems Biology  
doi:10.1038/msb4100016 
 
Borry, P., P. Schotsmans, and K. Dierickx. 2005. The birth of the empirical turn in 
bioethics. Bioethics 19 (1): 49-71. 
 
Bothwell, J. H. F. 2006. The long past of systems biology. New Phytologist 170: 
6-10. 
 
Brent, R. 2004. A partnership between biology and engineering. Nature 
Biotechnology 22 (10): 1211-1214. 
 
Brent, R., and Bruck, J. 2006. Can computers help explain biology? Nature 440: 
416-417 
 
Brodwin, P. 2002. Genetics, identify, and the anthropology of essentialism. 
Anthropological Quarterly 75 (2): 323-330. 
 
Brown, N., B. Rappert, and A. Webster. 2000. Contested Futures: A Sociology of 
Prospective Techno-science. Aldershot: Ashgate Press. 
 
Butcher, E. C. 2005. Can cell systems biology rescue drug discovery? Nature 
Reviews Drug Discovery 4: 461-467. 
 
Butcher, E. C., E. L. Berg, and E. J. Kunkel. 2004. Systems biology in drug 
discovery. Nature Biotechnology 22 (10): 1253-1259. 
 
Cases, I., and de Lorenzo, V. 2005. Genetically modified organisms for the 
environment: stories of success and failure and what we have learned from them. 
International Microbiology 8: 213-222. 
 
 26 
Cassman, M., A. Arkin, F. Katagiri, D. Lauffenburger, F. J. Doyle, and C. L. 
Stokes. 2005. Barriers to progress in systems biology. Nature 438: 1079. 
 
Check, E. 2005. Synthetic biologists face up to security issues. Nature 436: 894-
895. 
 
Church, G. M. 2005. From systems biology to synthetic biology. Molecular 
Systems Biology published online 29 March doi: 10.1038/msb4100007 
 
Clayton, E. W. 2001. Through the lens of the sequence. Genome Research 11: 
659-664. 
 
Compton, M. 2001. Unifying logic: searching for the biggest truths in the smallest 
elements. DNA Dispatch Jan 21. 
 
Cornish-Bowden, A. 2005. Making systems biology work in the 21st century. 
Genome Biology 6: 317 doi:10.1186/gb-2005-6-4-317 
 
Cornish-Bowden, A., and Cárdenas, M. L. 2005. Systems biology may work 
when we learn to understand the parts in terms of the whole. Biochemistry 
Society Transactions 33 (3): 516-519. 
 
Cornish-Bowden, A., M. L. Cárdenas, J. C. Letelier, J. Soto-Andrade, and F. G. 
Abarzúa. 2004. Understanding the parts in terms of the whole. Biology of the Cell 
96: 713-717. 
 
Csete, M. E., and Doyle, J. C. 2002. Reverse engineering of biological 
complexity. Science 295: 1664-1669. 
 
DeLong, E. F. 2002. Towards microbial systems science: integrating microbial 
perspectives, from genomes to biomes. Environmental Microbiology 4 (1): 9-10. 
 
 27 
Drexler, R. E. 2005. Productive nanosystems: the physics of molecular 
fabrication. Physics Education 40: 339-346. 
 
Dupré, J. 2004. Understanding contemporary genomics. Perspectives on 
Science 12: 320-338. 
 
Engineering and Physical Research Council (EPSRC). (2004). Research 
priorities and opportunities.  
www.epsrc.ac.uk/Content/Publications/Corporate/ResearchPrioritiesAndOpportu
nities.htm 
 
Ferber, D. 2004. Synthetic biology: microbes made to order. Science 303: 158-
161. 
 
Foster, M. W., and Sharp R. R. 2002. Race and ethnicity in the genome era: the 
complexity of the constructs.  Genome Research 12: 844-850. 
 
Fox Keller, E. 2005. The century beyond the gene. Journal of Biosciences 30 (1): 
101-108. 
 
Frewer, L., J. Larsen, B. Kettlitz, J. Scholderer, V. Beekman, and K. G. Berdal. 
2004. Societal aspects of genetically modified foods. Food and Chemical 
Toxicology 42: 1181=1193. 
 
Fujimura, J. H. 2005. Postgenomic futures: translations across the machine-
nature border in systems biology. New Genetics and Society 24 (2): 195-226. 
 
Goldman, M. 2002. A virtual pharmacopeia. Bio-IT World Nov 12, www.bio-
itworld.com/archive/111202/virtual.htm 
 
Greely, H. T. 1998. Legal, ethical and social issues in human genome research. 
Annual Review of Anthropology 27: 473-502. 
 28 
 
Handelsman, J. 2004. Metagenomics: applications of genomics to uncultured 
microorganisms. Microbiology and Molecular Biology Reviews 68 (4): 669-85. 
 
Heath, J. R., M. E. Phelps, and L. Hood. 2003. NanoSystems biology. Molecular 
Imaging and Biology 5 (5): 312-325. 
 
Hedgecoe, A. M. 2004. Critical bioethics: beyond the social science critique of 
applied ethics. Bioethics 18 (2): 120-143. 
 
Heller, M. A., and Eisenberg, R. S. 1998. Can patents deter innovation? The 
anticommons in biomedical research. Science 280: 698-701. 
 
Hood, H., and Galas, D. 2003. The digital code of DNA. Nature 421: 444-448. 
 
Hood, L., J. R. Heath, M. E. Phelps, and B. Lin. 2004. Systems biology and new 
technologies enable predictive and preventive medicine. Science 306: 640-643. 
 
Hood, L., and Perlmutter, R. M. 2004. The impact of systems approaches on 
biological problems in drug discovery. Nature Biotechnology 22 (10): 1215-1217. 
 
Huang, S. 2004. Back to the biology in systems biology: what can we learn from 
biomolecular networks? Briefings in Functional Genomics and Proteomics 2 (4): 
279-297. 
 
Ideker, T., T. Galitski,. and L. Hood. 2001. A new approach to decoding life: 
systems biology. Annual Review of Genomics and Human Genetics 2: 343-372. 
 
Ideker, T., L. R. Winslow, and A. D. Lauffenburger. 2006. Bioengineering and 
systems biology. Annals of Biomedical Engineering doi: 10.1007/s10439-005-
9047-7 
 
 29 
Kitano, H.  2002a. Computational systems biology. Nature 420: 206-210. 
 
Kitano, H. 2002b. Looking beyond the details: a rise in system-oriented 
approaches in genetics and molecular biology. Current Genetics 41: 1-10. 
 
Kitano, H. 2004a. Cancer as a robust system: implications for anticancer therapy. 
Nature Reviews Cancer 4: 227-235. 
 
Kitano. H. 2004b. Biological robustness. Nature Reviews Genetics 5 (11): 826-
837. 
 
Kling, J. 2006. Working the systems. Science 311: 1305-1306. 
 
Levy, N., and Lotz, M. 2005. Reproductive cloning and a (kind of) genetic fallacy. 
Bioethics 19:232-250. 
 
Lewens, T. 2002. Development aid: on ontogeny and ethics. Studies in the 
History and Philosophy of Biological and Biomedical Sciences 33: 195-217. 
 
Light, D. W., and McGee, G. 1998. On the social embeddedness of bioethics. In 
Bioethics and society: constructing the ethical enterprise, ed. R. DeVries and J. 
Subedi, 1-15, Upper Saddle River, NJ: Prentice-Hall. 
 
Liu, E. T. 2005. Systems biology, integrative biology, predictive biology. Cell 121: 
505-506. 
 
Mack, G. S. 2004. Can complexity be commercialized? Nature Biotechnology 22 
(10): 1223-1229. 
 
Marshall, E. 1996. The genome program’s conscience. Science 274 (5287): 488-
490. 
 
 30 
Maschio, T., and Kowalski, T. 2001. Bioinformatics – a patenting view. Trends in 
Biotechnology 19 (9): 334-339. 
 
Mauron, A. 2001. Is the genome the secular equivalent of the soul? Science 291: 
831-832. 
 
McGee, G. 2003. Beyond genetics: putting the power of DNA to work in your life. 
NY: William Morrow. 
 
McGuire, A. L., and Gibbs, R. A. 2006. No longer de-identified. Science 312: 370-
371. 
 
Mucke, H. A. M. 2005. A new paradigm for clinical development: the clinical trial 
in 2015. Cambridge: CHA Life Sciences. 
 
Musante, C. J., A. K. Lewis, and K. Hall. 2002. Small- and large-scale 
biosimulation applied to drug discovery and development. Drug Discovery Today 
7 (20), S192-S196. 
 
Mustacchi, R., S. Hohmann, and J. Nielsen. 2006. Yeast systems biology to 
unravel the network of life. Yeast 23: 227-238. 
 
Nature Biotechnology. 2005. Recent patent applications in systems biology. 
Nature Biotechnology 23: 939. 
 
Nature Editors. 2006. Bioethics at the bench. Nature 440: 1089-1090. 
 
Nee, S. 2005. More than meets the eye. Nature 429: 804-805. 
 
Nelkin, D. 2001. Molecular metaphors: the gene in popular discourse. Nature 
Reviews Genetics 2: 555-559. 
 
 31 
Newman, D. F., and Banfield, J. F. 2002. Geomicrobiology: how molecular-scale 
interactions underpin biogeochemical systems. Science 296: 1071-1077. 
 
Nicholson, J. K., E. Holmes, J. C. Lindon, and I. D. Wilson. 2004. The challenges 
of modeling mammalian biocomplexity. Nature Biotechnology 22 (10): 1268-
1274. 
 
Noble, D., J. Levin, and W. Scott. 1999. Biological simulations in drug discovery. 
Drug Discovery Today 4 (1): 10-16. 
 
Nuffield Council on Bioethics. 1999. Genetically Modified Crops. London: Nuffield 
Council. 
 
O’Malley, M. A., A. Bostanci, and J. Calvert. 2005. Whole-genome patenting. 
Nature Reviews Genetics 6: 502-7. 
 
O’Malley, M. A., and Dupré, J. 2005. Fundamental issues in systems biology.  
BioEssays 27: 1270-1276. 
 
O’Malley, M. A., and Dupré, J. In press. Size doesn’t matter: towards a more 
inclusive philosophy of biology. Biology and Philosophy. 
 
Palsson, B. 2000. The challenges of in silico biology. Nature Biotechnology 18: 
1147-1150. 
 
Patrinos, A., and Drell, D. W. 1997. The Human Genome Project: view from the 
Department of Energy. Journal of the American Medical Women’s Association 52 
(1): 8-10. 
 
Pazos, F., A. Valencia, and V. de Lorenzo. 2003. The organization of the 
microbial biodegradation network from a systems-biology perspective. EMBO 
Rep. 4 (10): 994-999. 
 32 
 
Pennisi, E. 2005. Synthetic biology remakes small genomes. Science 310: 769-
770. 
 
Perchaud, S. (2003). Software Patents and Innovation, Journal of Information, 
Law and Technology. 4 July 2003 (1)  
http://www2.warwick.ac.uk/fac/soc/law/elj/jilt/2003_1/perchaud 
 
Pilcher, H. 2006. Dial ‘E’ for ethics. Nature 440: 1104-1105. 
 
PricewaterhouseCoopers 1999. Pharma 2005. Silicon rally: the race to e-R&D. 
www.pwcglobal.com/gx/eng/about/ind/pharma/silicon_rally.pdf 
 
Rai, A. K. 2005. ‘Open and Collaborative’ Research: A New Model for 
Biomedicine. In Intellectual Property Rights in Frontier Industries: Software and 
Biotechnology, ed. R. W. Hahn, 131-158, Washington, DC: AEI-Brookings Joint 
Center for Regulatory Studies. 
 
Reiss, T. 2005. The take-off of European systems biology (EUSYSBIO). 
Karlsruhe: Fraunhofer Institute Systems and Innovation Research. 
 
Reiss, M. J., and Straughan, R. 1996. Improving Nature? Cambridge: Cambridge 
University Press.  
 
Relman, D. A., and Falkow, S. 2001. The meaning and impact of the human 
genome sequence for microbiology. Trends in Microbiology 9 (5): 206-208. 
 
Richards, M. 2001. How distinctive is genetic information? Studies in the History 
and Philosophy of Biological and Biomedical Sciences 32 (4): 663-687. 
 
Rifkin, J. 1998. The Biotech Century. London: Victor Gollancz.  
 
 33 
Robert, J. S. 2005. Systems bioethics. 
www.public.asu.edu/~jrobert6/systemsbioethics.htm 
 
Robertson, J. A. 2003. The $1000 genome: ethical and legal issues in whole 
genome sequencing of individuals. The American Journal of Bioethics 3 (3): 
W35-W42. 
 
Rodríguez-Valera, F. 2004. Environmental genomics – the big picture? FEMS 
Microbiology Letters 231 (2): 153-158. 
 
Russell, J. 2005. Harvard researchers discuss systems biology. Bio-IT World 
April 15, www.bio-itworld.com/newsitems/2005/07-05/07-20-05-Harvardinterview 
 
Russell, J. 2006a. Optimata, Entelos Win Simulation Patents. Bio-IT World Jan 
26, www.bio-itworld.com/newsitems/2006/january/01-26-06-news-biosimulation 
 
Russell, J. 2006b. Marvelous models of biological systems. Bio-IT World Feb 15, 
www.bio-itworld.com/issues/2006/feb/cover-story-models/ 
 
Sayler, G. S., and Ripp, S. 2000. Field applications of genetically engineered 
microorganisms for bioremediation processes. Current Opinion in Biotechnology 
11: 286-289. 
 
Selinger, D. W., M. A. Wright, and G. M. Church. 2003. On the complete 
determination of biological systems. Trends in Biotechnology 21 (6): 251-254. 
 
Stokes, L., and Arkin, A. 2005. Modelling and network organization. In 
International research and development in systems biology, ed. WTEC, 29-51. 
Baltimore, MD: WTEC Inc. 
 
 34 
Stotz, K., P. E. Griffiths, and R. Knight. 2004. How biologists conceptualize 
genes: an empirical study. Studies in the History and Philosophy of Biological 
and Biomedical Sciences 35: 647-673. 
 
Strange, K. 2005. The end of “naïve reductionism”: raise of systems biology or 
renaissance of physiology? Perspectives in Cell Physiology 288: C968-C974. 
 
Suter, S. M. 2001. The allure and peril of genetics exceptionalism: do we need 
special genetics legislation? Washington University Law Quarterly 79: 669-748. 
 
Tyson, G. W., J. Chapman, P. Hugenholz, E. E. Allen, R. J. Ram, P. M. 
Richardson, V. V. Solovyev, E. M. Rubin, D. S. Rokhsar, and J. F. Banfield. 
2004. Community structure and metabolism through reconstruction of microbial 
genomes from the environment. Nature 428: 37-43. 
 
Uehling, M. D. 2003. Model patient. Bio-IT World Dec 15, www.bio-
itworld.com/archive/121503/trials.htm 
 
US Department of Energy. 2005. GTL Roadmap: Systems Biology and Energy 
for the Environment. Germantown, MD: DOE Office of Science. 
 
Venter J. C., K. Remington, J. F Heidelberg,  A. L. Helper, D. Rusch, J. A  Eisen, 
D. Wu, I. Paulsen, K .E Nelson, W. Nelson, D. E. Fouts, S. Levy, A. H. Knap, M. 
W. Lomas, K. Nealson, O. White, J. Peterson, J. Hoffman, R. Parsons, H. Baden-
Tillson, C. Pfannkoch, Y. H. Rogers, and H. O Smith. 2004. Environmental 
genome shotgun sequencing of the Sargasso Sea. Science 304: 66-74. 
 
Volk, T. 2006. Real concerns, false gods. Nature 440: 869-870. 
 
Waters, M.D., and Fostel, J.M. 2004. Toxicogenomics and systems toxicology: 
aims and prospects. Nature Reviews Genetics 5 (12): 936-948. 
 
 35 
Westerhoff, H. V., and Palsson, B. O. 2004. The evolution of molecular biology 
into systems biology. Nature Biotechnology 22 (10): 1249-1252. 
 
Wolkenhauer, O. 2001. Systems biology: the reincarnation of systems theory 
applied in biology? Briefings in Bioinformatics 2 (3): 258-270. 
 
World Technology Evaluation Centre (WTEC). 2005. International research and 
development in systems biology. Baltimore, MD: WTEC Inc. 
 
Wynne, B. 2005. Reflexing complexity: post-genomic knowledge and reductionist 
returns in public science. Theory, Culture and Society 22 (5): 67-94. 
  
Zandonella, C. 2003. Cell nanotechnology: the tiny toolkit. Nature 423: 10-12. 
 
Zussman, R. 2000. The contributions of sociology to medical ethics. Hastings 
Center Report 30 (1): 7-11. 
